At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with metastatic non-small cell lung cancer.
No takes yet. Share an insight, caveat, or question.
Bradley et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: